Fresenius Kabi Oncology has received approval from Securities and Exchange Board of India (SEBI) to delist its shares from the Indian stock market. As per the SEBI’s order, the healthcare firm has to complete the delisting process within three months. The market regulator also said that the company would have to take into account its pre-OFS (Offer for Sale) promoter holding of October 2012 to determine the minimum number of shares to be acquired for the delisting.
As on September 2012, Fresenius Kabi (Singapore) Pte, the parent firm held 90% stake in the company, while remaining 10% stake were with the public shareholders.
Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.
